Effectiveness of neuronavigation in resecting solitary intracerebral contrast-enhancing tumors: a randomized controlled trial.
OBJECTIVE
The goal of this study was to assess the impact of neuronavigation on the cytoreductive treatment of solitary contrast-enhancing intracerebral tumors and outcomes of this treatment in cases in which neuronavigation was preoperatively judged to be redundant.


METHODS
The authors conducted a prospective randomized study in which 45 patients, each harboring a solitary contrast-enhancing intracerebral tumor, were randomized for surgery with or without neuronavigation. Peri- and postoperative parameters under investigation included the following: duration of the procedure; surgeon's estimate of the usefulness of neuronavigation; quantification of the extent of resection, determined using magnetic resonance imaging; and the postoperative course, as evaluated by neurological examinations, the patient's quality-of-life self-assessment, application of the Barthel index and the Karnofsky Performance Scale score, and the patient's time of death. The mean amount of residual tumor tissue was 28.9% for standard surgery (SS) and 13.8% for surgery involving neuronavigation (SN). The corresponding mean amounts of residual contrast-enhancing tumor tissue were 29.2 and 24.4%, respectively. These differences were not significant. Gross-total removal (GTR) was achieved in five patients who underwent SS and in three who underwent SN. Median survival was significantly shorter in the SN group (5.6 months compared with 9 months, unadjusted hazard ratio = 1.6); however, this difference may be attributable to the coincidental early death of three patients in the SN group. No discernible important effect on the patients' 3-month postoperative course was identified.


CONCLUSIONS
There is no rationale for the routine use of neuronavigation to improve the extent of tumor resection and prognosis in patients harboring a solitary enhancing intracerebral lesion when neuronavigation is not already deemed advantageous because of the size or location of the lesion.
Department of Neurosurgery, University Medical Center Utrecht, The Netherlands. p.willems@neuro.azu.nl
Peter W A
PW
Willems
Martin J B
MJ
Taphoorn
Huib
H
Burger
Jan Willem
JW
Berkelbach van der Sprenkel
Cees A F
CA
Tulleken
D000368:Aged; D001932:Brain Neoplasms / Q000601:surgery*; D003287:Contrast Media / Q000008:administration & dosage; D005260:Female; D005909:Glioblastoma / Q000601:surgery*; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D038361:Neuronavigation / Q000379:methods*; D011379:Prognosis; D011446:Prospective Studies; D011788:Quality of Life; D013238:Stereotaxic Techniques; D016019:Survival Analysis; D016896:Treatment Outcome
D003287:Contrast Media